Role of Proprotein Convertase Subtilisin Kexin Type 9 Inhibitor Therapy in Treatment of Patients With Polycystic Ovary Syndrome: A Systemic Review of Metabolic and Cardiovascular Outcomes
DOI:
https://doi.org/10.56570/jimgs.v1i1.149Keywords:
Polycystic Ovary Syndrome (PCOS), PCSK9 inhibitors, Dyslipidemia management, Cardio-metabolic complications, Statins vs. PCSK9 efficacyAbstract
Polycystic Ovary Syndrome (PCOS) is a common endocrine condition that affects both obese and non-obese women of reproductive age group. Its clinical presentation is dysmenorrhea, hirsutism, acne, metabolic complications, infertility, and polycystic ovaries. The study is aimed to assess the efficacy of Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) Inhibitors to lower dyslipidemia in women with PCOS to prevent long term cardio-metabolic complications. PCSK 9 Inhibitors ( Alirocumab, Evolocumab, and Inclisiran) bind to LDL receptors in liver and lower LDL-C levels, preventing long term adverse side effects. This review aims at showing that these drugs can be effective when prescribed to women with PCOS early-on to prevent some serious cardiovascular and metabolic complications in the long run. In terms of medical therapy, most physicians prescribe Metformin and Statins as first line agents to control risk factors. But much of the research supported the use of PCSK 9 Inhibitors early in the disease process or as an add-on to statins for controlling the lipid profile. When compared to Statins, the control rates of PCSK 9 Inhibitors were equal or superior and they showed additive effect when given along with other lipid lowering agents. Studies showed these drugs have only minor side effects and have good tolerability profile. They do not have severe side effects as compared to statins or fibrates.References
Goodman NF, Cobin RH, Futterweit W, Glueck JS, Legro RS, Carmina E. AMERICAN ASSOCIATION OF CLINICAL ENDOCRINOLOGISTS, AMERICAN COLLEGE OF ENDOCRINOLOGY, AND ANDROGEN EXCESS AND PCOS SOCIETY DISEASE STATE CLINICAL REVIEW: GUIDE TO THE BEST PRACTICES IN THE EVALUATION AND TREATMENT OF POLYCYSTIC OVARY SYNDROME - PART 1. Endocrine Practice. 2015;21(11):1291-1300. doi:https://doi.org/10.4158/ep15748.dsc
What are the symptoms of PCOS? https://www.nichd.nih.gov/. Published January 31, 2017. https://www.nichd.nih.gov/health/topics/pcos/conditio ninfo/symptoms
Crespo RP, Bachega TASS, Mendonça BB, Gomes LG. An update of genetic basis of PCOS pathogenesis. Archives of Endocrinology and Metabolism. 2018;62(3):352-361.doi:https://doi.org/10.20945/2359-3997000000049
What We Talk About When We Talk About PCOS. www.vice.com. https://www.vice.com/en/article/zmae5j/what-we-talk-about-when-we-talk-about-pcos
About Polycystic Ovary Syndrome (PCOS). https://www.nichd.nih.gov/. https://www.nichd.nih.gov/health/topics/pcos/conditio ninfo
Dawood A, Goyal M. Debates regarding lean patients with polycystic ovary syndrome: A narrative review. Journal of Human Reproductive Sciences. 2017;10(3):154.doi:https://doi.org/10.4103/jhrs.jhrs_77_17
Legro RS, Arslanian SA, Ehrmann DA, et al. Diagnosis and Treatment of Polycystic Ovary Syndrome: An Endocrine Society Clinical Practice Guideline. The Journal of Clinical Endocrinology & Metabolism. 2013;98(12):4565-4592.doi:https://doi.org/10.1210/jc.2013-2350
Polycystic Ovarian Syndrome Treatment & Management: Approach Considerations, Lifestyle Modifications, Drug Treatment. Medscape.com. Published September 16, 2018. https://emedicine.medscape.com/article/256806-treatment
Huang G, Coviello A. Clinical update on screening, diagnosis and management of metabolic disorders and cardiovascular risk factors associated with polycystic ovary syndrome. Current Opinion in Endocrinology & Diabetes and Obesity. 2012;19(6):512-519. doi:https://doi.org/10.1097/med.0b013e32835a000e
Wang FF, Wu Y, Zhu YH, et al. Pharmacologic therapy to induce weight loss in women who have obesity/overweight with polycystic ovary syndrome: a systematic review and network meta-analysis. Obesity Reviews. 2018;19(10):1424-1445.doi:https://doi.org/10.1111/obr.12720
Liu Q, Xie Y, Qu L, Zhang M, Mo Z. Dyslipidemia involvement in the development of polycystic ovary syndrome. Taiwanese Journal of Obstetrics and Gynecology. 2019;58(4):447-453.doi:https://doi.org/10.1016/j.tjog.2019.05.003
Wild RA, Rizzo M, Clifton S, Carmina E. Lipid levels in polycystic ovary syndrome: systematic review and meta-analysis. Fertility and Sterility. 2011;95(3):1073-1079.e11.doi:https://doi.org/10.1016/j.fertnstert.2010.12.027
Wekker V, van Dammen L, Koning A, et al. Long-term cardiometabolic disease risk in women with PCOS: a systematic review and meta-analysis. Human Reproduction Update. 2020;26(6):942-960. doi:https://doi.org/10.1093/humupd/dmaa029
Zhu S, Zhang B, Jiang X, et al. Metabolic disturbances in non-obese women with polycystic ovary syndrome: a systematic review and meta-analysis. Fertility and Sterility. 2019;111(1):168-177. doi:https://doi.org/10.1016/j.fertnstert.2018.09.013
Zhao L, Zhu Z, Lou H, et al. Polycystic ovary syndrome (PCOS) and the risk of coronary heart disease (CHD): a meta-analysis. Oncotarget. 2016;7(23):33715-33721.doi:https://doi.org/10.18632/oncotarget.9553
Yanes L, Romero DG, Reckelhoff JF. Cardiometabolic Features of Polycystic Ovary Syndrome: Role of Androgens. Physiology. 2017;32(5):357-366. doi:https://doi.org/10.1152/physiol.00030.2016
Osibogun O, Ogunmoroti O, Michos ED. Polycystic ovary syndrome and cardiometabolic risk: Opportunities for cardiovascular disease prevention. Trends in Cardiovascular Medicine. 2020;30(7):399-404. doi:https://doi.org/10.1016/j.tcm.2019.08.010
Sanchez-Garrido MA, Tena-Sempere M. Metabolic dysfunction in polycystic ovary syndrome: Pathogenic role of androgen excess and potential therapeutic strategies. Molecular Metabolism. 2020;35:100937. doi:https://doi.org/10.1016/j.molmet.2020.01.001
Yang R, Yang S, Li R, Liu P, Qiao J, Zhang Y. Effects of hyperandrogenism on metabolic abnormalities in patients with polycystic ovary syndrome: a meta-analysis. Reproductive Biology and Endocrinology. 2016;14(1). doi:https://doi.org/10.1186/s12958-016-0203-8
Valkenburg O, R.P.M. Steegers‐Theunissen, H.P.M. Smedts, et al. A More Atherogenic Serum Lipoprotein Profile Is Present in Women with Polycystic Ovary Syndrome: A Case-Control Study. The Journal of Clinical Endocrinology and Metabolism. 2008;93(2):470-476. doi:https://doi.org/10.1210/jc.2007-1756
Zhang Y, Suo Y, Yang L, et al. Effect of PCSK9 Inhibitor on Blood Lipid Levels in Patients with High and Very-High CVD Risk: A Systematic Review and Meta-Analysis. Cardiology Research and Practice. 2022;2022:1-13.doi:https://doi.org/10.1155/2022/8729003
Bergeron N, Phan BAP, Ding Y, Fong A, Krauss RM. Proprotein Convertase Subtilisin/Kexin Type 9 Inhibition. Circulation. 2015;132(17):1648-1666. doi:https://doi.org/10.1161/circulationaha.115.016080
Li C, Lin L, Zhang W, et al. Efficiency and Safety of Proprotein Convertase Subtilisin/Kexin 9 Monoclonal Antibody on Hypercholesterolemia: A Meta‐Analysis of 20 Randomized Controlled Trials. 2015;4(6). doi:https://doi.org/10.1161/jaha.115.001937
Bär S, Räber I, Koskinas KC, Christoph Schlapbach, Lorenz Räber. Transient injection site reaction to alirocumab during immune system activation: a case series. European Heart Journal - Case Reports. 2022;6(5). doi:https://doi.org/10.1093/ehjcr/ytac187
di Mauro G, Zinzi A, Scavone C, et al. PCSK9 Inhibitors and Neurocognitive Adverse Drug Reactions: Analysis of Individual Case Safety Reports from the Eudravigilance Database. Drug Safety. 2020;44(3):337-349.doi:https://doi.org/10.1007/s40264-020-01021-3
Kazi DS, Moran AE, Coxson PG, et al. Cost-effectiveness of PCSK9 Inhibitor Therapy in Patients With Heterozygous Familial Hypercholesterolemia or Atherosclerotic Cardiovascular Disease. JAMA. 2016;316(7):743.doi:https://doi.org/10.1001/jama.2016.11004
Kosmas CE, Skavdis A, Sourlas A, et al. Safety and Tolerability of PCSK9 Inhibitors: Current Insights. Clinical Pharmacology : Advances and Applications. 2020;12:191-202. doi:https://doi.org/10.2147/CPAA.S288831
amilial Hypercholesterolemia and Pregnancy. American College of Cardiology. https://www.acc.org/latest-in-cardiology/articles/2018/05/10/13/51/familial-hypercholesterolemia-and-pregnancy#:~:text=PCSK9%20inhibitors%20have%2 0not%20been
Wang M, Zhao D, Xu L, et al. Role of PCSK9 in lipid metabolic disorders and ovarian dysfunction in polycystic ovary syndrome. Metabolism. 2019;94:47-58. doi:10.1016/j.metabol.2019.02.002
Bizoń A, Franik G, Madej P. The role of proprotein convertase subtilisin/kexin type-9 concentration and paraoxonase 1 activities in the blood of women with polycystic ovary syndrome. Environ Toxicol Pharmacol. 2021;84:103612. doi:10.1016/j.etap.2021.103612
Moazzeni DR. PCSK9 Inhibitors: The New Frontier in Cholesterol Management. Heartcare Sydney. Published August 20, 2023. https://heartcare.sydney/pcsk9-inhibitors/
Schulz R, Andreadou I, Ferdinandy P. Editorial: PCSK9: Importance in Physiology and Pathophysiology. Frontiers in Physiology. 2021;12. doi:https://doi.org/10.3389/fphys.2021.706115
